logo
#

Latest news with #PrecisionSuite

ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions
ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions

Business Wire

time31-05-2025

  • Business
  • Business Wire

ConcertAI Provides Intelligent Automation of ASCO ® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ ® SmartLinQ™ Solutions

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite's low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes. In December of 2023, ASCO and ConcertAI announced the acquisition of CancerLinQ and ongoing network operations as a ConcertAI initiative. Over the last year and a half, ConcertAI has advanced the SmartLinQ application for QOPI® applications as well as advanced notifications of potentially beneficial diagnostics and newly approved therapeutics for a provider's patients. SmartLinQ works directly within the workflows of Epic and other EMRs. ASCO Guidelines will be augmenting the SmartLinQ solution by June 15th as part of the company's effort to assure that all network practices have that informational resource. On May 30 th, ConcertAI announced its oncology Precision Suite™ of generative and agentic AI solutions for advancing analytics and inferences, and for clinical trial design and optimization. The ASCO Guidelines will be available within these solutions by June 30 th for assessment of Guideline-concordant care across the widest array of settings, and to inform the design of clinical trial controls according to published clinical recommendations. 'Through CancerLinQ, ConcertAI has an almost decade-long history of collaborating with ASCO,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This license of ASCO Guidelines represents a new opportunity to harness the latest generative and agentic AI technologies to promote high-quality cancer care, evidence generation, and advanced care insights.' The CancerLinQ SmartLinQ deployment of these guidelines will be available to demonstrate at the 2025 ASCO Annual Meeting in Chicago. About ConcertAI: ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at

ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences

Business Wire

time30-05-2025

  • Business
  • Business Wire

ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value. The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem. Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results. Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies. Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand. Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets. 'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.' 'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.' Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications. About ConcertAI: ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store